STIM - ニュ―ロネティクス (Neuronetics Inc.)

STIMのニュース

   Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2022/08/05 20:30:00 GlobeNewswire
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee''s entry into employment with the Company.
   Neuronetics, Inc. (STIM) Q2 2022 Earnings Call Transcript  2022/08/03 02:30:53 The Motley Fool
STIM earnings call for the period ending June 30, 2022.
   Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results - Earnings Call Transcript  2022/08/02 16:52:12 Seeking Alpha
Neuronetics Inc (NASDAQ:NASDAQ:STIM) Q2 2022 Earnings Conference Call August 2, 2022 08:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO…
   Neuronetics, Inc. 2022 Q2 - Results - Earnings Call Presentation  2022/08/02 15:39:10 Seeking Alpha
The following slide deck was published by Neuronetics, Inc.
   Recap: Neuronetics Q2 Earnings  2022/08/02 12:40:34 Benzinga
Neuronetics (NASDAQ: STIM ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Neuronetics beat estimated earnings by 4.88%, reporting an EPS of $-0.39 versus an … Full story available on Benzinga.com
   A Quick Glance At Neuronetics Inc. (NASDAQ: STIM) Stock: It Is up 10.26% From Its 52-Week Low; YTD, It Is Down -30.04 Percent  2022/04/02 13:00:00 Marketing Sentinel
During the last session, Neuronetics Inc. (NASDAQ:STIM)’s traded shares were 0.34 million, with the beta value of the company hitting 2.36. At the end of the trading day, the stock’s price was $3.12, reflecting an intraday gain of 2.97% or $0.09. The 52-week high for the STIM share is $17.92, that puts it down -474.36 … A Quick Glance At Neuronetics Inc. (NASDAQ: STIM) Stock: It Is up 10.26% From Its 52-Week Low; YTD, It Is Down -30.04 Percent Read More »
   Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2022/03/08 21:35:00 GlobeNewswire
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to five new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee''s entry into employment with the Company.
   Neuronetics, Inc. (STIM) Q4 2021 Earnings Call Transcript  2022/03/08 21:00:41 The Motley Fool
STIM earnings call for the period ending December 31, 2021.
   Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales  2022/03/08 20:16:06 Benzinga
Neuronetics Inc (NASDAQ: STIM ) reported Q4 FY21 sales of $15.02 million , down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y due to lower NeuroStar Advanced Therapy System sales and treatment session … Full story available on Benzinga.com
   Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2021 Earnings Call Transcript  2022/03/08 18:43:02 Seeking Alpha
   Neuronetics Launches Enhanced Digital Resource Center for NeuroStar Providers  2021/07/14 12:15:00 Intrado Digital Media
The redesigned My NeuroStar Resource Center provides user-friendly tools to help practices expand awareness of NeuroStar® Advanced Therapy for Mental Health The redesigned My NeuroStar Resource Center provides user-friendly tools to help practices expand awareness of NeuroStar® Advanced Therapy for Mental Health
   Latest Research Report On Transcranial Magnetic Stimulators Market 2021. Major Players Included Neuronetics, Yiruide, Magstim, Brainsway, Neurosoft, etc.  2021/07/12 05:43:19 Tramways Monthly
The Transcranial Magnetic Stimulators Market is a rapidly growing and developing industry. This report will help you gather the information needed to either enter this space or take advantage of the many opportunities in it. DataIntelo published a great research report on the Transcranial Magnetic Stimulators Market which will help you in taking the right []
   Neuronetics to join Russell 2000 Index  2021/06/24 11:43:35 Seeking Alpha
   Neuronetics Set to Join Russell 2000® Index  2021/06/23 21:29:00 Intrado Digital Media
MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.
   Neuronetics Set to Join Russell 2000 Index  2021/06/23 21:29:00 Wallstreet:Online
MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the company will be added to the Russell 2000 Index at the conclusion of the 2021 Russell indexes annual

calendar